Intelligence Feed event · Capital · 2026-09-25

    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share

    Question

    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share

    Direct answer

    ADARx Pharmaceuticals, a clinical-stage biotech focused on siRNA therapeutic modalities, successfully priced its upsized initial public offering at $17.00 per share, raising $446.3 million in gross proceeds. Shares are scheduled to begin trading on the Nasdaq under ticker ADRX on September 25, 2026, offering a benchmark read on late-stage biotech issuance appetite in an elevated interest rate environment.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-nasdaq-ipo-at-17-share-733384

    CAPITAL
    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share
    ADARx Pharmaceuticals, a clinical-stage biotech focused on siRNA therapeutic modalities, successfully priced its upsized initial public offering at $17.00 per share, raising $446.3 million in gross proceeds. Shares are scheduled to begin trading on the Nasdaq under ticker ADRX on September 25, 2026, offering a benchmark read on late-stage biotech issuance appetite in an elevated interest rate environment.
    ADRX
    Impact
    71
    SEP 25
    SIG
    95%
    ADRX
    ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share
    ADARx Pharmaceuticals, a clinical-stage biotech focused on siRNA therapeutic modalities, successfully priced its upsized initial public offering at $17.00 per share, raising $446.3 million in gross proceeds. Shares are scheduled to begin trading on the Nasdaq under ticker ADRX on September 25, 2026, offering a benchmark read on late-stage biotech issuance appetite in an elevated interest rate environment.
    → Capital deployment into clinical-stage siRNA pipeline expands public market biotech supply and tests primary ECM demand.
    Impact
    ADARx Pharmaceuticals, a clinical-stage biotech focused on siRNA therapeutic modalities, successfully priced its upsized initial public offering at $17.00 per share, raising $446.3 million in gross proceeds. Shares are scheduled to begin trading on the Nasdaq under ticker ADRX on September 25, 2026, offering a benchmark read on late-stage biotech issuance appetite in an elevated interest rate environment.
    Affected
    ADRX
    Transmission
    Capital deployment into clinical-stage siRNA pipeline expands public market biotech supply and tests primary ECM demand.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXprimary market pricing and Nasdaq debut tradingWatchintradayADARx priced 26.25M shares at $17.00 to raise $446.3M gross proceeds.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    ADRXWatch19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month